Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Endocrinology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunonutrition for Diabetic Foot Ulcers
Details : Lovaza is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Diabetes Mellitus.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 16, 2022
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Endocrinology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Woodward Pharma Services
Deal Size : Undisclosed
Deal Type : Acquisition
Woodward Pharma Services LLC Acquires LOVAZA(R) Capsules
Details : Woodward Pharma Services LLC, has acquired Lovaza (LO-VEY-ZA) soft gelatin capsules indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia from GlaxoSmithKline...
Product Name : Lovaza
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Woodward Pharma Services
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Omega-3-Acid Ethyl Esters is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertriglyceridemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 16, 2021
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Drug-drug Interaction of Omega-3 and Atorvastatin
Details : Omega-3 Acid Ethyl Esters is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hyperlipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2018
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : University of Oslo | Rikshospitalet University Hospital | Ullevaal University Hospital | Drammen sykehus | Fuzhou Children's Hospital | South-Eastern Norway Regional Health Authority | Aalborg University | PRONOVA BIOPHARMA NORGE AS | Haukeland University
Deal Size : Inapplicable
Deal Type : Inapplicable
The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation
Details : Omega-3 Acid Ethyl Esters is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Transplantation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2017
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : University of Oslo | Rikshospitalet University Hospital | Ullevaal University Hospital | Drammen sykehus | Fuzhou Children's Hospital | South-Eastern Norway Regional Health Authority | Aalborg University | PRONOVA BIOPHARMA NORGE AS | Haukeland University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAK-085 is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hyperlipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 21, 2016
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAK-085 is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hyperlipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 06, 2016
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides
Details : Omega-3 Acid Ethyl Esters is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertriglyceridemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2015
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Omega-3 Acid Ethyl Esters is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 02, 2014
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of TAK-085 in Participants With Hypertriglyceridemia
Details : Omega-3 Acid Ethyl Esters is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertriglyceridemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 10, 2011
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
